SYK Stock Analysis: Buy, Sell, or Hold?
SYK - Stryker Corporation
$329.59
2.15 (0.66%)
▲
5d:
-0.9%
30d:
-14.94%
90d:
-6.95%
HOLD
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
SYK is down 5.6% this week, but smart money is accumulating calls. Top strike: $400 2026-06-18 with 604 OI. Call ratio: 66% View Scanner →
Strength: 4.4/10
Get Alerted When SYK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SYK shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SYK shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$559.82
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$347.60
5.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SYK is currently trading at $329.59, which is considered oversold relative to its 30-day fair value range of $338.06 to $380.88. From a valuation perspective, the stock is trading at a discount (Forward PE: 19.6) compared to its historical average (22.9). Remarkably, the market is currently pricing in an annual earnings decline of 5.1% over the next few years. This pessimistic expectation contrasts with the company's recent 55.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SYK is showing sideways momentum. The price is currently testing key support at $324.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SYK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $425.08 (+29.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SYK is showing sideways momentum. The price is currently testing key support at $324.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SYK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $425.08 (+29.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$338.06 -
$380.88
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding SYK? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.8% below Wall St target ($425.08)
Fair Price Analysis
30-Day Fair Range
$338.06 -
$380.88
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$324.93
Resistance Level
$355.75
Current Trend
Sideways
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.56
Wall Street Target
$425.08
(+29.8%)
Revenue Growth (YoY)
11.4%
Earnings Growth (YoY)
55.9%
Profit Margin
12.9%
Valuation Discount vs History
-5.1% cheaper
PE vs Historical
19.6 vs 22.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.1%
(market-implied from PE analysis)
1-Year Target
$310.74
(-5%)
2-Year Target
$294.89
(-10%)
3-Year Target
$279.85
(-15%)
3-Yr Target (if PE normalizes)
(PE: 20→23)
$327.68
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 11.8%)
$524.46
(+60%)
Base:
(SPY PE: 19.6, Growth: 11.8%)
$457.91
(+40%)
Bear:
(PE: 16.6, Growth: 11.8%)
$389.22
(+19%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 40.01 | Current EPS (TTM): $8.39
Bull Case
$736.42
(+121%)
Analyst growth 99.4%, PE expands to 44.0
Base Case
$669.47
(+101%)
Market implied 99.4%, PE stable at 40.0
Bear Case
$228.26
(-31%)
Severe decline -20.0%, PE contracts to 34.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.6 to 22.9
Stabilization Target:
$383.40
(+17.1%)
PE Expansion Potential:
+17.1%
Share & Embed Analysis
Last updated: March 30, 2026 10:05 AM ET
Data refreshes hourly during market hours. Next update: 11:05 AM
Data refreshes hourly during market hours. Next update: 11:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SYK showing a specific setup today?
Insider Activity (6 Months)
6
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-02-24
Ro Khanna
BUY
2026-02-17
Ronda E Stryker
SELL
250000 shares
2026-02-04
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 48 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 56 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 56 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$96 | 53 HOLD |
Advanced SYK Option Strategies
Professional options setups generated by AI based on today's SYK price and gamma walls.
